However, administration of a glucagon receptor antagonist (GRA) does not seem to affect postprandial glucose excursions in patients with type 2 diabetes [11], indicating that glucagon is important for glucose homeostasis in the fasting state rather than postprandially. The gene discussed is GCG; the disease is type 2 diabetes mellitus.